NEW YORK (GenomeWeb News) – Cepheid today said that Canadian regulatory authorities have cleared for marketing the firm’s molecular diagnostic assay for methicillin-resistant Staphylococcus aureus and Staphylococcus aureus in skin and soft tissue infections.
 
The Xpert MRSA/SA SSTI test runs on Cepheid’s GeneXpert System and can provide test results in less than an hour. The firm noted that its test is the first molecular SSTI diagnostic for MRSA and SA to be cleared in Canada.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.